November 24, 2021
Bristol Myers Squibb’s second CAR-T cell therapy idecabtagene vicleucel (ide-cel) will come up for discussion at a key Japanese health ministry advisory committee on December 6. If given the nod, it will be in line for approval as the country’s...read more